In an effort to evaluate the need for targeted therapies in MCC, Brunner et al. examined 32 samples from 29 patients with MCC and found that VEGF-A, which is a proangiogenic factor, was expressed in more than 90% of them [200]. This evidence concerns the gene VEGFA and Merkel cell skin cancer.